PRMT5 and breast carcinoma: Previous reports have shown that PRMT5 silencing slows tumor growth in vivo, using xenograft models from cancer‐derived cell lines, including the breast cancer‐derived MCF7.39, 44 In alignment with these reports, we here show that pharmacological inhibition of PRMT5 slows tumor growth in a TNBC PDX model.